<DOC>
	<DOCNO>NCT00062257</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irofulven , use different way stop tumor cell divide stop grow die . PURPOSE : This phase II trial study well irofulven work treat patient recurrent metastatic gastric cancer .</brief_summary>
	<brief_title>Irofulven Treating Patients With Recurrent Metastatic Gastric Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient recurrent metastatic gastric cancer treat irofulven . - Determine toxicity profile drug patient . - Determine overall survival patient treated drug . OUTLINE : This non-randomized , open-label , multicenter study . Patients receive irofulven IV 30 minute day 1 8 . Courses repeat every 3 week absence disease progression , unacceptable toxicity , static disease 4 course absence clinical benefit . Patients follow survival . PROJECTED ACCRUAL : A total 20-35 patient accrue study within 5-9 month .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm gastric adenocarcinoma Recurrent metastatic disease Adenocarcinoma gastroesophageal junction eligible provide majority tumor bulk junction Measurable disease At least 1 lesion least 20 mm conventional technique OR least 10 mm spiral CT scan No known brain metastasis PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 02 Life expectancy More 3 month Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 No active disseminate intravascular coagulation Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) AST/ALT great 2.5 time ULN ( 5 time ULN patient liver metastasis ) Alkaline phosphatase great 5 time ULN Renal Creatinine great 1.5 time ULN Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction attribute compound similar chemical biological composition irofulven No malignancy within past 5 year except adequately treat carcinoma situ cervix basal cell squamous cell skin cancer No uncontrolled concurrent illness would preclude study participation No ongoing active infection No psychiatric illness social situation would preclude study compliance Must central peripherally inserted central catheter PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent filgrastim ( GCSF ) , sargramostim ( GMCSF ) , epoetin alfa Chemotherapy No prior chemotherapy recurrent metastatic disease Prior adjuvant neoadjuvant chemotherapy allow provided disease relapse 6 month therapy Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy recover Surgery Not specify Other No concurrent investigational commercial agent therapy malignancy No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
</DOC>